Is CFRXQ or RYLD a better dividend investment in 2026?

CFRXQ currently yields 20000000.00% with a 5% 5-year dividend growth rate. RYLD yields 12.14% with 5% growth. The better choice depends on your goal: CFRXQ offers higher current income.

What is the dividend yield difference between CFRXQ and RYLD?

CFRXQ has a forward dividend yield of 20000000.00% ($2.00/share annually). RYLD yields 12.14% ($1.81/share annually). The yield gap is 19999987.86 percentage points.

Home › Compare › CFRXQ vs RYLD

CFRXQ vs RYLD: Dividend Comparison 2026

CFRXQ yields 20000000.00% · RYLD yields 12.14%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CFRXQ wins by $4.875981653489057e+49M in total portfolio value

INVESTMENT

TIME HORIZON10 years

CFRXQ

● Live price

20000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875981653489057e+49M

Annual income

$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full CFRXQ calculator →

RYLD

● Live price

12.14%

Share price

$14.95

Annual div

$1.81

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.5K

Annual income

$2,587.35

Full RYLD calculator →

Portfolio growth — CFRXQ vs RYLD

📍 CFRXQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CFRXQ	RYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CFRXQ + RYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CFRXQ pays

RYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CFRXQ

Annual income on $10K today (after 15% tax)

$1,700,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

RYLD

Annual income on $10K today (after 15% tax)

$1,031.60/yr

After 10yr DRIP, annual income (after tax)

$2,199.25/yr

At 15% tax rate, CFRXQ beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CFRXQ + RYLD for your $10,000?

CFRXQ: 50%RYLD: 50%

100% RYLD50/50100% CFRXQ

Portfolio after 10yr

$2.4379908267445285e+49M

Annual income

$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CFRXQ right now

CFRXQ

Analyst Ratings

Buy

Consensus: Buy

Altman Z

-63.9

Piotroski

0/9

RYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CFRXQ buys

RYLD buys

No recent congressional trades found for CFRXQ or RYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCFRXQRYLD

Forward yield	20000000.00% ✓	12.14%
Annual dividend / share	$2.00 ✓	$1.81
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.875981653489057e+49M	$44.5K ✓
Annual income after 10y	$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$2,587.35
Total dividends collected	$4.875978515990276e+49M	$18.8K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CFRXQ vs RYLD ($10,000, DRIP)

Year	CFRXQ Portfolio	CFRXQ Income/yr	RYLD Portfolio	RYLD Income/yr	Gap
1← crossover	$2,000,010,700	$2,000,000,000.00	$11,914	$1,213.65	+$2000.00M → CFRXQ
2	$373,835,915,712,384	$373,833,775,700,934.50	$14,099	$1,351.30	+$373835915.70M → CFRXQ
3	$65,304,953,364,964,970,000	$65,304,553,360,535,160,000.00	$16,580	$1,494.55	+$65304953364964.95M → CFRXQ
4	$10,661,728,832,755,500,000,000,000	$10,661,658,956,455,399,000,000,000.00	$19,384	$1,642.61	+$10661728832755499008.00M → CFRXQ
5	$1,626,767,783,781,495,000,000,000,000,000	$1,626,756,375,731,643,800,000,000,000,000.00	$22,535	$1,794.70	+$1.626767783781495e+24M → CFRXQ
6	$231,974,330,054,625,100,000,000,000,000,000,000	$231,972,589,413,096,470,000,000,000,000,000,000.00	$26,063	$1,950.00	+$2.319743300546251e+29M → CFRXQ
7	$30,915,106,403,922,057,000,000,000,000,000,000,000,000	$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00	$29,995	$2,107.69	+$3.0915106403922057e+34M → CFRXQ
8	$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000	$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00	$34,361	$2,266.99	+$3.8505079858392777e+39M → CFRXQ
9	$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000	$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00	$39,194	$2,427.12	+$4.4821026103531426e+44M → CFRXQ
10	$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000	$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$44,525	$2,587.35	+$4.875981653489057e+49M → CFRXQ

CFRXQ vs RYLD: Complete Analysis 2026

CFRXQ — Stock

ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. On December 4, 2023, ContraFect Corporation filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Full CFRXQ Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →

📬

Get this CFRXQ vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CFRXQ vs SCHD CFRXQ vs JEPI CFRXQ vs O CFRXQ vs KO CFRXQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.